Aminoglycoside Dosing Calculator

Aminoglycosides bind irreversibly to the 30S ribosomal subunit, causing misreading of messenger RNA and membrane damage during uptake, which makes them rapidly bactericidal against aerobic gram-negative organisms. Killing is concentration-dependent: efficacy tracks the ratio of peak concentration to the organism minimum inhibitory concentration, with a target Cmax/MIC around 8 to 10, and a post-antibiotic effect keeps growth suppressed for hours after levels fall below the MIC. Typical extended-interval doses are 7 mg/kg for gentamicin and tobramycin and 15 mg/kg for amikacin, whose higher figure reflects its higher MIC breakpoints rather than lower potency per milligram. Because the molecules are hydrophilic cations they stay in extracellular fluid, so the volume of distribution is modelled at about 0.25 L/kg and dosing uses adjusted body weight, ideal weight plus 0.4 of the excess, once actual weight exceeds 120 percent of ideal. Elimination is almost entirely glomerular, which is why the elimination rate constant is estimated directly from creatinine clearance using ke = 0.00293 x CrCl + 0.014 and why the dosing interval, not the dose, is what gets stretched in renal impairment, commonly to 36 hours below 60 mL/min and 48 hours below 40. Troughs are pushed below 1 microgram/mL to allow washout from proximal tubular cells, since nephrotoxicity occurs in roughly 10 to 25 percent of courses and correlates with accumulation rather than peak. Ototoxicity, mediated by hair cell loss, is the more feared injury because it is often permanent. Model-based estimates also fail in expanded or contracted fluid compartments, so burns, ascites, cystic fibrosis and septic capillary leak demand measured levels.

The class began with streptomycin, isolated in 1943 by Albert Schatz working in Selman Waksman's soil microbiology laboratory at Rutgers University from the actinomycete Streptomyces griseus. It was the first drug effective against tuberculosis, and Waksman received the Nobel Prize in Physiology or Medicine in 1952. Neomycin followed from the same laboratory in 1949, kanamycin was described by Hamao Umezawa in Japan in 1957, tobramycin was derived from Streptomyces tenebrarius in the 1960s, and amikacin was produced in the early 1970s as a semisynthetic derivative of kanamycin A, acylated to block several bacterial inactivating enzymes and so retain activity against resistant gram-negatives. Dosing science lagged behind discovery. Through the 1960s and 1970s these drugs were given as fixed doses every eight hours, and the resulting kidney and ear injury nearly drove them out of use as safer beta-lactams arrived. Quantitative dosing arrived when Sarubbi and Hull published their pharmacokinetic method in the Annals of Internal Medicine in 1978, linking the elimination rate constant to estimated creatinine clearance in the linear form still used in this calculator. Animal work in the 1980s then showed that renal cortical uptake saturates, meaning a single large daily dose accumulates less drug in the kidney than divided doses of the same total. Once-daily programmes were implemented and audited in large clinical cohorts during the 1990s, and extended-interval administration became the default for most indications, with divided synergy dosing retained mainly for endocarditis.